Johnson & Johnson

1. 01

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: +5.2% (SPY −2.6%, XLV +9.9%). 3 months: +4.4% (SPY −2.2%, XLV +13.5%). 1 year: +42.9% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: JNJ, SPY and XLV · as of 3 Nov 2026

2. 02

   P/E 36.6% below its peers' median

   Trailing P/E of 40.4 against a median of 63.7 across 4 peers named in its company record (range 40.4 to 118.7).

   Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 3 Nov 2026

3. 03

   Above its 50- and 200-day averages

   The 3 Nov 2026 close of $266.17 was 0.3% above its 50-day average ($265.47) and 7.6% above its 200-day average ($247.48). It has closed above the 200-day for 329 sessions, since 16 Jul 2025. The 50-day average crossed above the 200-day on 24 Jul 2025, 322 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026

4. 04

   Next ex-dividend date: 24 Nov 2026

   $1.34 a share, payable 8 Dec 2026; unchanged from the previous payment (ex-date 25 Aug 2026).

   Corporate actions record · as of 4 Nov 2026

5. 05

   84% of the way up its 52-week range

   Closed at $266.17 on 3 Nov 2026: 5.6% below the 52-week high of $282.02 (30 Oct 2026) and 43.8% above the low of $185.12 (10 Nov 2025).

   Daily price bars, split-adjusted · as of 3 Nov 2026

At the 3 Nov 2026 close